- Frequency Exchange (FREQ) has engaged several top doctors to form an advisory group to support its wellness and performance enhancement technology
- The advisory group was assembled based on their skill sets and ability to advise management in the field of frequency wellness and performance
- Frequency Exchange Corp. (FREQ) is focused on the development and commercialization of a frequency emitter that delivers a special package of frequencies designed for the health and wellness market, specifically to target Lyme disease within North America
- Frequency Exchange (FREQ) was up 6.25 trading at $0.085 a share as of 10:50 am ET
Frequency Exchange’s (FREQ) subsidiary, FREmedica Technologies has engaged several top doctors to form an advisory group.
The group will support the company’s wellness and performance enhancement technology.
Robert Cass, N.D., Leigh Erin Connealy, M.D. and Christine Schaffner, N.D. and Scott Forsgren, FDN-P joins the team to support the development of the “NIKKI” and the “WAVE 1” to help people who are struggling with Lyme disease.
From experience as master formulators to operating clinic networks, the advisory group was assembled based on their skill sets and ability to advise management in the field of frequency wellness and performance.
Frequency Exchange CEO Stephen Davis stated that “bringing the inspiration and experience of these frequency wellness and performance pioneers to our team will further speed our progress in overcoming the fastest growing tick-borne disease along with enhancing our wellness and performance.”
Frequency Exchange Corp. (FREQ) is focused on the development and commercialization of a frequency emitter that delivers a special package of frequencies designed for the health and wellness market, specifically to target Lyme disease within North America.
Frequency Exchange (FREQ) was up 6.25 trading at $0.085 a share as of 10:50 am ET.